These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 32623818)

  • 81. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
    Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
    N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Multicenter Experience with Nusinersen Application via an Intrathecal Port and Catheter System in Spinal Muscular Atrophy.
    Flotats-Bastardas M; Hahn A; Schwartz O; Linsler S; Meyer S; Kolodziej M; Koehler C
    Neuropediatrics; 2020 Dec; 51(6):401-406. PubMed ID: 33091940
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: A case report focusing on the neurofilament light chain in cerebrospinal fluid.
    Tozawa T; Kasai T; Tatebe H; Shiomi K; Nishio H; Tokuda T; Chiyonobu T
    Brain Dev; 2020 Mar; 42(3):311-314. PubMed ID: 31889567
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers.
    Chen E; Dixon S; Naik R; Noone JM; Buchenberger JD; Whitmire SM; Mills R; Arnold W
    Muscle Nerve; 2021 Mar; 63(3):311-319. PubMed ID: 33184859
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cytochemical Characterization of Cerebrospinal Fluid Macrophage Inclusions in Pediatric Patients Receiving Intrathecal Nusinersen (SPINRAZA®) for Spinal Muscular Atrophy.
    Schafernak KT; Jacobsen JR; Hernandez D; Kaye RD; Perez SE
    Acta Cytol; 2022; 66(1):79-84. PubMed ID: 34515035
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Feasibility analysis of intrathecal administration strategy of nusinersen based on Cobb angle in children with spinal muscular atrophy.
    Huang J; Feng Y; Wang J; Huang S; Jin J; Xu L; Zhao C; Hua Y; Li X; Xu J; Li H; Zhang H; Zhang Y; Gao F; Mao S
    Eur J Paediatr Neurol; 2023 Sep; 46():55-60. PubMed ID: 37453233
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: What about spine and hip?
    Yasar NE; Ozdemir G; Uzun Ata E; Ayvali MO; Ata N; Ulgu M; Dumlupınar E; Birinci S; Bingol I; Bekmez S
    J Child Orthop; 2024 Jun; 18(3):322-330. PubMed ID: 38831860
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Simple Fluoroscopy-Guided Transforaminal Lumbar Puncture: Safety and Effectiveness of a Coaxial Curved-Needle Technique in Patients with Spinal Muscular Atrophy and Complex Spines.
    Jacobson JP; Cristiano BC; Hoss DR
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):183-188. PubMed ID: 31831464
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy].
    Mao SS; Feng YJ; Xu L; Yao M; Xia Y; Jin JN; Wang LS; Chen TT; Chen XY; Zhang Y; Zhang H; Jiang Y; Li HB; Long Q; Gao F
    Zhonghua Er Ke Za Zhi; 2022 Jul; 60(7):688-693. PubMed ID: 35768357
    [No Abstract]   [Full Text] [Related]  

  • 92. Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review Study.
    Elman L; Youn B; Proud CM; Frey MR; Ajroud-Driss S; McCormick ME; Michelson D; Cartwright MS; Heiman-Patterson T; Choi JM; Chandak A; Khachatryan A; Martinez M; Paradis AD
    J Neuromuscul Dis; 2022; 9(5):655-660. PubMed ID: 36031906
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Intrathecal administration of nusinersen for spinal muscular atrophy: report of three cases with severe spinal deformity.
    Nakao S; Yamada S; Tsuda K; Yokomizo T; Sato T; Tanoue S; Hiraki T
    JA Clin Rep; 2020 Apr; 6(1):28. PubMed ID: 32314319
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
    Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
    Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
    Dutta D; Chandra G; Mohanakumar KP
    J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Ultrasound-guided nusinersen administration for spinal muscular atrophy patients with severe scoliosis: an observational study.
    Zhang J; Cui X; Chen S; Dai Y; Huang Y; Zhang S
    Orphanet J Rare Dis; 2021 Jun; 16(1):274. PubMed ID: 34120632
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Modified nusinersen intrathecal injection method: inclusion of a septal needle-free closed infusion connector.
    Zhang Y; Zheng K; Liang C; Zheng R; Chen J; Jiang M; Zhou Z; Zhao Y; Rao M; Yang S; Chen W; Liu L
    Front Neurol; 2023; 14():1234442. PubMed ID: 37808480
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Ultrasound-guided lumbar puncture for nusinersen administration in spinal muscular atrophy patients.
    Veiga-Canuto D; Cifrián-Pérez M; Pitarch-Castellano I; Vázquez-Costa JF; Aparici F
    Eur J Neurol; 2021 Feb; 28(2):676-680. PubMed ID: 33051940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.